+Compare
NBIX
Stock ticker:
NASDAQ
AS OF
Jul 1 closing price
Price
$99.25
Change
+$1.77 (+1.82%)
Capitalization
9.49B

NBIX Price Prediction, Neurocrine Biosciences AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Jul 01, 2022

NBIX in upward trend: price rose above 50-day moving average on June 17, 2022

NBIX moved above its 50-day moving average on June 17, 2022 date and that indicates a change from a downward trend to an upward trend. In 30 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 24, 2022. You may want to consider a long position or call options on NBIX as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on June 23, 2022. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for NBIX crossed bullishly above the 50-day moving average on June 07, 2022. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 305 cases where NBIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for NBIX moved out of overbought territory on June 09, 2022. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.821) is normal, around the industry mean (8.023). P/E Ratio (135.135) is within average values for comparable stocks, (43.381). NBIX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.543). NBIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.022). P/S Ratio (8.032) is also within normal values, averaging (66.127).

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

NBIX is expected to report earnings to rise 335.00% to 60 cents per share on August 02

Neurocrine Biosciences NBIX Stock Earnings Reports
Q2'22
Est.
$0.61
Q1'22
Missed
by $0.21
Q4'21
Missed
by $0.76
Q3'21
Missed
by $0.33
Q2'21
Missed
by $0.07
The last earnings report on May 04 showed earnings per share of 14 cents, missing the estimate of 34 cents. With 655.90K shares outstanding, the current market capitalization sits at 9.49B.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Endo International plc (NASDAQ:ENDP).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 1.76B. The market cap for tickers in the group ranges from 246 to 81.99B. ZTS holds the highest valuation in this group at 81.99B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -1%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -23%. TCNAF experienced the highest price growth at 628%, while INNPF experienced the biggest fall at -98%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 14%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was -50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 71
Price Growth Rating: 74
SMR Rating: 61
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a product based biopharmaceutical company

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12780 El Camino Real
Phone
+1 858 617-7600
Employees
900
Web
https://www.neurocrine.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RVLP1.410.05
+3.68%
RVL Pharmaceuticals plc
WMS91.891.82
+2.02%
Advanced Drainage Systems
IRWD11.53N/A
N/A
Ironwood Pharmaceuticals
RTLR13.64-0.01
-0.07%
Rattler Midstream LP
CETX0.28N/A
-1.04%
Cemtrex

NBIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with ITCI. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then ITCI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+1.82%
ITCI - NBIX
47%
Loosely correlated
-3.35%
ZTS - NBIX
33%
Loosely correlated
+1.35%
OGI - NBIX
33%
Poorly correlated
+2.52%
ELAN - NBIX
33%
Poorly correlated
+5.04%
NLTX - NBIX
33%
Poorly correlated
-3.87%
More